Literature DB >> 34378462

Assessing Interventions That Prevent Multiple Infectious Diseases: Simple Methods for Multidisease Modeling.

Anneke L Claypool1, Jeremy D Goldhaber-Fiebert2, Margaret L Brandeau1.   

Abstract

BACKGROUND: Many cost-effectiveness analyses (CEAs) only consider outcomes for a single disease when comparing interventions that prevent or treat 1 disease (e.g., vaccination) to interventions that prevent or treat multiple diseases (e.g., vector control to prevent mosquito-borne diseases). An intervention targeted to a single disease may be preferred to a broader intervention in a single-disease model, but this conclusion might change if outcomes from the additional diseases were included. However, multidisease models are often complex and difficult to construct.
METHODS: We present conditions for when multiple diseases should be considered in such a CEA. We propose methods for estimating health outcomes and costs associated with control of additional diseases using parallel single-disease models. Parallel modeling can incorporate competing mortality and coinfection from multiple diseases while maintaining model simplicity. We illustrate our approach with a CEA that compares a dengue vaccine, a chikungunya vaccine, and mosquito control via insecticide and mosquito nets, which can prevent dengue, chikungunya, Zika, and yellow fever.
RESULTS: The parallel models and the multidisease model generated similar estimates of disease incidence and deaths with much less complexity. When using this method in our case study, considering only chikungunya and dengue, the preferred strategy was insecticide. A broader strategy-insecticide plus long-lasting insecticide-treated nets-was not preferred when Zika and yellow fever were included, suggesting the conclusion is robust even without the explicit inclusion of all affected diseases. LIMITATIONS: Parallel modeling assumes independent probabilities of infection for each disease.
CONCLUSIONS: When multidisease effects are important, our parallel modeling method can be used to model multiple diseases accurately while avoiding additional complexity.

Entities:  

Keywords:  coinfection; competing mortality; cost-effectiveness analysis; infectious disease; mathematical modeling

Mesh:

Substances:

Year:  2021        PMID: 34378462      PMCID: PMC8831671          DOI: 10.1177/0272989X211033287

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.749


  13 in total

Review 1.  The epidemiology of yellow fever in Africa.

Authors:  John-Paul Mutebi; Alan D T Barrett
Journal:  Microbes Infect       Date:  2002-11       Impact factor: 2.700

2.  The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia.

Authors:  Alexia Kieffer; Celine Hoestlandt; Yaneth Gil-Rojas; Anaïs Broban; Camilo Castañeda-Cardona; Diego Rosselli
Journal:  Value Health Reg Issues       Date:  2019-04-08

3.  You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses.

Authors:  Rudolf T Hoogenveen; Hendriek C Boshuizen; Peter M Engelfriet; Pieter H M van Baal
Journal:  Med Decis Making       Date:  2016-07-12       Impact factor: 2.583

4.  Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions.

Authors:  Janel Hanmer; David Vanness; Ronald Gangnon; Mari Palta; Dennis G Fryback
Journal:  J Clin Epidemiol       Date:  2009-11-06       Impact factor: 6.437

5.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.

Authors:  Van-Mai Cao-Lormeau; Alexandre Blake; Sandrine Mons; Stéphane Lastère; Claudine Roche; Jessica Vanhomwegen; Timothée Dub; Laure Baudouin; Anita Teissier; Philippe Larre; Anne-Laure Vial; Christophe Decam; Valérie Choumet; Susan K Halstead; Hugh J Willison; Lucile Musset; Jean-Claude Manuguerra; Philippe Despres; Emmanuel Fournier; Henri-Pierre Mallet; Didier Musso; Arnaud Fontanet; Jean Neil; Frédéric Ghawché
Journal:  Lancet       Date:  2016-03-02       Impact factor: 79.321

6.  Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections.

Authors:  A Desirée Labeaud; Fatima Bashir; Charles H King
Journal:  Popul Health Metr       Date:  2011-01-10

7.  Costs of dengue to the health system and individuals in Colombia from 2010 to 2012.

Authors:  Raul Castro Rodriguez; Katia Galera-Gelvez; Juan Guillermo López Yescas; Jorge A Rueda-Gallardo
Journal:  Am J Trop Med Hyg       Date:  2015-02-09       Impact factor: 2.345

8.  Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis.

Authors:  Anneke L Claypool; Margaret L Brandeau; Jeremy D Goldhaber-Fiebert
Journal:  PLoS Negl Trop Dis       Date:  2021-12-29

9.  A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control.

Authors:  Jorge A Alfaro-Murillo; Alyssa S Parpia; Meagan C Fitzpatrick; Jules A Tamagnan; Jan Medlock; Martial L Ndeffo-Mbah; Durland Fish; María L Ávila-Agüero; Rodrigo Marín; Albert I Ko; Alison P Galvani
Journal:  PLoS Negl Trop Dis       Date:  2016-05-20

10.  Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia.

Authors:  Affan Shoukat; Thomas Vilches; Seyed M Moghadas
Journal:  BMC Med       Date:  2018-07-03       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.